Research Catalog

Use of left ventricular assist devices as destination therapy in end-stage congestive heart failure : a systematic review

Title
Use of left ventricular assist devices as destination therapy in end-stage congestive heart failure : a systematic review / Thomas S. Rector [and four others].
Author
Rector, Thomas S.
Publication
Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, 2012.

Available Online

0

Details

Additional Authors
  • Quality Enhancement Research Initiative (U.S.)
  • United States. Department of Veterans Affairs. Health Services Research and Development Service, issuing body.
  • Minneapolis VA Health Care System (U.S.). VA Evidence Synthesis Program.
  • Evidence-based Synthesis Program (U.S.)
Description
1 online resource (iii, 41 pages) : illustrations
Summary
Heart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (<25%) who were not candidates for heart transplantation due to their age or co-morbid conditions. The purpose of this report is to review the scientific evidence for use of the current generation of left ventricular assist devices as destination therapy.
Subject
  • Heart failure > Treatment > United States
  • Heart > Left ventricle > Diseases > United States
  • Outcome assessment (Medical care) > United States
  • Mathematical models
  • Heart failure > Treatment
  • Heart > Left ventricle > Diseases
  • Outcome assessment (Medical care)
  • United States
Note
  • "Evidence-based synthesis program."
  • "May 2012."
Bibliography (note)
  • Includes bibliographical references (pages 24-26).
Funding (note)
  • VA-ESP
Source of Description (note)
  • Description based on online resource; title from PDF cover (VA, viewed April 22, 2021).
Call Number
GPO Internet VA 1.107/3:V 55
OCLC
marcive815716442
Author
Rector, Thomas S., author.
Title
Use of left ventricular assist devices as destination therapy in end-stage congestive heart failure : a systematic review / Thomas S. Rector [and four others].
Publisher
Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, 2012.
Type of Content
text
Type of Medium
computer
Type of Carrier
online resource
Bibliography
Includes bibliographical references (pages 24-26).
Funding
VA-ESP 09-009
Connect to:
https://purl.fdlp.gov/GPO/gpo154951
Added Author
Quality Enhancement Research Initiative (U.S.)
United States. Department of Veterans Affairs. Health Services Research and Development Service, issuing body.
Minneapolis VA Health Care System (U.S.). VA Evidence Synthesis Program.
Evidence-based Synthesis Program (U.S.)
Gpo Item No.
0985-A-12 (online)
Sudoc No.
VA 1.107/3:V 55
View in Legacy Catalog